The bioproduction franchise, now augmented by proprietary filtration technology embedded in biologics manufacturing workflows, locks TMO into drug production processes where switching mid-campaign is costly and risky. As biologics pipelines mature into commercial production, this positions TMO to capture recurring consumables and services revenue. The thesis breaks if pharma customers shift to single-use or modular systems from alternative suppliers, visible as flattening bioproduction organic growth or margin erosion from competitive pricing.
the thesis · admitted · the reason above is the thesis, not printed twice
no findingread · nothing bore on it
It held on this filing. No finding was written because nothing in it bore on the reason — the sentences it was read against are below.
the evidence · every sentence checkedthree sentences · whole, uncut
the claims it rests on · in our words, not the filing’s